The US Food and Drug Administration (FDA) has approved Journavx, a new pain reliever without the risks of addiction or overdose linked to drugs like Vicodin and OxyContin.

The U.S. Food and Drug Administration said it approved Vertex Pharmaceuticals’ Journavx for short-term pain that often ...

the most common side effects experienced by study participants after taking Journavx included muscle spasms, itching, and rashes. Suzetrigine belongs to a new class of non-opioid pain medications ...

The new non-opioid drug has been approved for the treatment of severe pain, such as that following surgery or an injury.

The drug, Journavx by Vertex Pharmaceuticals, blocks pain signals to the brain, making it nonaddictive. The Food and Drug ...

ensuring suzetrigine’s inclusion in outpatient and surgical settings while reducing reliance on opioids," he said. The most common side effects of Journavx, according to the company’s website ...

The FDA approved Vertex Pharmaceuticals’ Journavx, a new non-opioid pain pill for short-term pain. While safer than opioids, ...

The Vertex drug is a milestone after a long history of unsuccessful efforts to develop painkillers without the addictive potential of opioids.